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Statement of findings
Iodinated oestradiol-labeled oestrogen receptor (ER) isoforms devoid of amino-terminal ABC
domains represent about two-thirds of the whole receptor population detected in cytosol
samples from human breast cancers. This high frequency could not be ascribed to the
expression of truncated mRNAs, or to the proteolysis of the native ER peptide at the time of
homogenization or assay, suggesting an intracellular proteolysis. Free amino-terminal and
ligand-binding domains maintained together within oligomeric structure(s); increase of ionic
strength separated them. The amino-terminal region was consistently detected in the cell
nucleus by specific immunohistochemistry leading to the concept of a potential intranuclear
association between ER cleavage products and/or other regulatory proteins.
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AEBSF = 4-[2-aminoethyl]-benzenesulphonyl fluoride; DCC = dextran-coated charcoal; EI = hydroxylapatite extraction index; ER = oestrogen
receptor; FPLC = fast pressure liquid chromatography; HAP = hydroxylapatite; IS = immunostaining score; Kd = dissociation constant; PAGE =
polyacrylamide gel electrophoresis; PMSF = phenylmethylsulphonylfluoride; SDS = sodium dodecyl sulphate; TAZ = tamoxifen aziridine.
Introduction: We previously reported that about two-thirds of
[125I]oestradiol-labelled cytosolic ERs from breast cancer
samples eluted as low-molecular-weight isoforms (£37 kDa, size-
exclusion fast pressure liquid chromatography [FPLC]). These
isoforms failed to adsorb strongly to hydroxylapatite at high ionic
strength, a property that was ascribed to receptors devoid of
amino-terminal ABC domains. In view of recent data concerning
intracellular proteolysis of several transcriptional regulators, the
possibility of such behaviour for ER was assessed.
The clinical significance of ER measurement in breast cancer
cytosols is well established; approximately 50% of ER-positive
cases respond to endocrine therapy. Whether such a poor
correlation is related to a high proportion of cleaved ER is a
question of prime importance. Failure of routine ER assays to
discriminate between full-length and cleaved receptors led us to
develop an oestradiol-binding assay based on hydroxylapatite
adsorption.
The aims of the present study were to demonstrate that
hydroxylapatite adsorption assay easily identifies cleaved
cytosolic ER forms and to assess the origin of such ER forms.
Materials and methods: Breast cancer cytosols classified as
ER-positive according to [3H]oestradiol-binding assay (dextran-
coated charcoal [DCC]) were subjected to hydroxylapatite
adsorption. ER isoforms covalently labeled with [125I]tamoxifen
aziridine (TAZ) released from this matrix with 0.5 mol/l KCl
were subsequently immunoprecipitated with a panel of
monoclonal antibodies raised against various domains of ER
(H222 [E], H226 [C] or ER1D5 [AB]) before being subjected
to SDS-gel electrophoresis.
Three approaches were used to identify the origins of the
cleaved ER forms: potential truncated ER-a messenger RNAs
that may encode ER isoforms of low molecular weights
(Northern blot assay) were sought by using ER-a full-length
probe; heat treatment of tumour cytosols in the absence or
http://breast-cancer-research.com/content/2/6/444http://breast-cancer-research.com/content/2/6/444
Introduction
Assessment of the ER status in breast cancer samples is
currently used to select patients for endocrine (tamoxifen)
therapy [1–3]. Biochemical determinations of receptor con-
centration are based on the measurement of the tritiated
oestradiol-binding capacity of cytosol samples; immunoen-
zymatic measurements (Abbott’s ER enzyme immunoas-
say) usually give similar data because they use monoclonal
antibodies against epitopes that are localized at both
edges of the hormone-binding domain (E domain) [4]. His-
tochemical data established with various anti-ER mono-
clonal antibodies are in agreement with these biochemical
assays, at least on a qualitative basis [5–7]. Of note, histo-
chemical determinations identify ER essentially in the cell
nucleus, leading to the concept of a possible dissociation
of nuclear oligomers with concomitant release of the recep-
tor into the cytosol at the time of homogenization.
Approximately 50% of ER-positive breast cancers respond
to endocrine therapy [8]. A defect in the synthesis and/or
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presence of a cocktail of protease inhibitors was performed;
and the molecular weight of intracellular ER molecules was
determined by in situ [125I]TAZ-labelling, which minimizes ER
proteolysis.
Breast cancer samples classified as ER-positive according to
both biochemical (cytosolic DCC assay) and histochemical
(ER1D5 monoclonal antibody) criteria were labelled with
[3H]oestradiol and were subsequently subjected to
hydroxylapatite adsorption. Hydroxylapatite extraction index (EI)
is defined as a ratio of the specifically bound [3H]oestradiol
released from the hydroxylapatite matrix with KCl to the total
amount of the specifically bound [3H]oestradiol extracted
successively with KCl and ethanol: EI = ([3H]oestradiol)
[KCl] × 100/([3H]oestradiol) [KCl] + ([3H]oestradiol) [EtOH].
The EI was calculated for each cytosol in order to evaluate the
amount of cleaved ER forms present. Persistence of adsorption
ER to hydroxylapatite in the presence of KCl (low EI) and
ER1D5 positivity established by immunohistochemistry are two
independent criteria for the presence of amino-terminal ABC
domains. We therefore assessed whether hydroxylapatite
determinations performed on cytosols are related to immuno-
histochemistry data.
Results: Cytosol pools labelled with [125I]TAZ gave different
electrophoretic patterns depending on the nature of the anti-ER
monoclonal antibody used in the immunoprecipitation step
preceding electrophoresis. The carboxyl-terminal-specific
antibody H222 precipitated all ER isoforms (full-length 67 kDa
ER, and cleavage products of 50 and 37–28 kDa), whereas the
amino-terminal-specific antibodies H226 and ER1D5
precipitated only the full-length and a partially truncated isoform.
Adsorption of this labelled cytosol pool onto hydroxylapatite
with subsequent KCl extraction yielded ER isoforms with
molecular weights between 37 and 28 kDa when immuno-
precipitation of the elutes was carried out using H222. The
absence of these isoforms after exposure of the elutes to H226
or ER1D5 demonstrated truncation of these isoforms at a
site(s) downstream of ABC domains.
Total RNA from 46 tumours was exposed to ER-a full-length
probe (Northern blot). All tumours expressed a full-length 6.6-
kb ER mRNA; small-sized isoforms were not recorded. A good
correlation resulted when amounts of 6.6-kb ER mRNA
estimated by densitometry were compared with corresponding
[3H]oestradiol-binding capacities (DCC assay), thereby
rejecting the concept that low-molecular-weight isoforms were
encoded by truncated ER mRNA.
We next investigated whether such isoforms might be
generated by proteolysis. Cytosol samples of a series of breast
tumours were labelled with [125I]TAZ in the presence of a
cocktail of protease inhibitors. These inhibitors failed to
maintain the full-length 67 kDa ER by SDS-PAGE. In situ
[125I]TAZ-labelling of receptors associated with a protein
extraction procedure minimizing their proteolysis displayed
multi-bands electrophoretic patterns, almost identical to those
found under conventional methods. Hence, ER molecular
heterogeneity appears to result from an intracellular proteolysis.
ER1D5 immunostaining scores (ISs) of a series of 15 tumours
were significantly correlated with ER levels, as measured by
hydroxylapatite assay of corresponding cytosols (total number
of binding sites). Sequential extraction of bound [3H]oestradiol
from hydroxylapatite with KCl and ethanol revealed an EI of
over 30% in the large majority of these cytosols, indicating a
high frequency of cleaved ER isoforms. Of note, no significant
correlation between IS and EI data was recorded, suggesting
that ABC and E domains are separated at high ionic strength,
but are apparently held together within the cell nucleus in
oligomeric structures.
Discussion: Endogenous proteolysis is a regulatory
mechanism in many cellular processes, such as cell cycle
progression and transcriptional regulation. The present data
extend this concept to ER. Indeed, proteolysis-generated ER
fragments appear to be held together within the cell in
oligomeric structures. Because ER proteolysis is probably
relevant to several oestrogen target tissues, we suggest that
the protein environment, which differs among tissues, may be a
factor of major importance in the formation of distinct
oligomeric structures, which elicit specific biological
responses. The possibility of heterogeneous association
between cleaved ER and regulatory proteins might perhaps
result in a spectrum of such transcriptional activities. In this
context, we propose that a complementary hydroxylapatite
extraction assay (EI assessment) should be added to the usual
tests to identify ER-positive tumours. Such a complementary
test would provide an estimate of the level of cleaved ER forms,
which may have biological and/or clinical relevance.Breast Cancer Research    Vol 2 No 6 Maaroufi et al
turnover of ER that leads to the emergence of altered
receptors has been suggested as an explanation for this
relatively poor correlation between treatment response and
ER status [9,10]. In agreement with this, we found that
about two-thirds of [125I]oestradiol-labelled cytosolic ERs
elute as low-molecular-weight isoforms (£37 kDa, by size
exclusion FPLC) that fail to adsorb strongly to hydroxylap-
atite at high ionic strength [11], a property ascribed to
receptors that are devoid of amino-terminal ABC domains
[12] required for transcription activity. ER proteolysis may
lead to such a situation. Thus, a differential susceptibility of
the hinge region (D domain) that separates such ABC
domains from the hormone-binding domain to endoprote-
olytic cleavage has long been recognized [13]; whole
hormone-binding domain itself also contains a few specific
motifs that are accessible to proteolytic attacks [14,15]. Of
note, an oestradiol-inductible protease activity, which is
detected in mouse reproductive tissues, has been reported
to produce a cleaved ER that is devoid of its amino-termi-
nal region, but which has a nuclear localization capacity
[16]. Hence, cleaved ER isoforms may maintain a regula-
tory activity at the genomic level.
The relevance of the molecular heterogeneity of ER in
breast cancer is still a matter of controversy [17,18]. Our
observation that a given ER cleavage pattern is relevant to
the whole tumour mass (ie various samples taken from a
given patient usually display identical radiolabelled SDS-
PAGE profiles when their receptor isoforms were labelled
with [3H]TAZ [19]) accredit the analysis of this question.
Whether ER degradation occurs within the cell or is a
product of homogenization or assay is a question of prime
interest, in view of recent data regarding the biological sig-
nificance of intracellular proteolysis of transcriptional regu-
lators, such as the nuclear factor-kB, p53, c-JUN,
sterol-regulated element-binding proteins and MATa2
[20,21]. Of note, activation of nuclear factor-kB requires
proteasome-dependent proteolysis, leading to the process-
ing of a precursor (nuclear factor-kB1) into the mature form
[22]. Association of nuclear factor-kB with a specific
inhibitory protein (IkB), which masks its nuclear localization
signal, constitutes a functional system in which DNA
binding/activation and regulatory/inhibitory functions are
performed by two separate proteins that can interact [23].
Similar association of distinct functional domains may be
applicable to cleaved ER isoforms, because the native form
is also subject to proteasomal degradation [24–26].
In the present paper we demonstrate that ER isoforms of
low molecular weight could not be ascribed to the expres-
sion of truncated mRNAs, or to the proteolysis of the
native peptide at the time of assay, suggesting a degrada-
tive mechanism at the intracellular level. Moreover, we
establish systematic immunohistochemical identification of
ER amino-terminal domains within the cell nucleus with an
anti-ER monoclonal antibody (ER1D5) that is raised
against this part of the receptor molecule. All of these find-
ings support the concept of a potential intranuclear asso-
ciation between cleaved ER and other regulatory proteins.
Materials and methods
Reagents
[3H]oestradiol (approximately 100 Ci/mmol) was obtained
from Amersham (Buckinghamshire, UK); [125I]TAZ
(approximately 2000 Ci/mmol) was obtained from Trigone
Ligands/Biocode (Liège, Belgium); and unlabelled oestra-
diol was obtained from Sigma (St Louis, MO, USA).
Reagents for SDS-PAGE as well as Bio-Gel HTP hydroxyl-
apatite were from Bio-Rad (Richmond, CA, USA); and
H222 and H226 anti-ER monoclonal antibodies were a
gift from Dr D Cotter (Abbott Laboratories, North Chicago,
IL, USA). ER1D5 anti-ER monoclonal antibody was from
Immunotech (Marseille-Luminy, France). Protease
inhibitors (AEBSF, 4-[2-aminoethyl]-benzenesulphonyl flu-
oride; PMSF, phenylmethylsulphonylfluoride; antipain; chy-
mostatin; leupeptin; and calpastatin] were from Euro
Biochem (Bierges, Belgium).
Oestrogen receptor preparations
Primary breast cancer samples (for steroid hormone
receptor measurements) were obtained from our surgery
department. For ER measurement, they were homoge-
nized in 10 mmol/l phosphate (pH 7.4) containing
1 mmol/l EDTA and 1 mmol/l monothioglycerol using a
whole glass homogenizer. Homogenates were subse-
quently centrifuged for 1 h at 100000 g. Supernatants
were stored in liquid nitrogen until they were labelled,
which was within the following week.
Human full-length ER produced in yeast [27] was pro-
vided by Dr P Sjöholm (Karo Bio, Huddinge, Sweden).
This preparation was at a concentration of approximately
1 pmol/ml phosphate buffer (pH 7.5), and was stored at
–70°C. For experiments, aliquots were diluted with
10 mmol/l Tris-HCl buffer (pH 8), containing bovine serum
albumin (fraction V; Sigma) to reach a final protein con-
centration of approximately 1 mg/ml.
Cytosols from MCF-7 cells growing in monolayer culture
were prepared as described previously [28].
Oestrogen receptor assays
Dextran-coated charcoal assay
ER preparations were labelled with increasing concentra-
tions of [3H]oestradiol (range 0.25–5 nmol/l) in the
absence and presence of a 200-fold excess of unlabelled
oestradiol (overnight incubation at 0°C) and unbound
ligands were removed using the DCC adsorption method
(0.5% charcoal, 0.05% dextran) [29]. Specific binding was
calculated from the difference between radioactivity levels
measured in the absence and presence of unlabelled
oestradiol. Binding capacities were expressed per mil-http://breast-cancer-research.com/content/2/6/444
ligram of protein, the latter being measured using the Bio-
Rad assay. Parameters of the binding reaction (n, number
of binding sites; Kd, dissociation constant) were estimated
using the LIGAND v4.5 program (Dr PJ Munson, National
Institutes of Health, Bethesda, MD, USA), and the data
were plotted according to the method of Scatchard [30].
The same procedure was applied for [125I]TAZ, except that
a 5 nmol/l saturating concentration was used.
Hydroxylapatite assay and extraction index
ER preparations adsorbed on hydroxylapatite pellets (pre-
pared in 10 mmol/l Tris-HCl buffer, pH 8) were labelled
with increasing concentrations of [3H]oestradiol (range
0.25–5 nmol/l) in the presence and absence of a 200-fold
excess of unlabelled oestradiol (overnight incubation at
0°C) [12]. Bound [3H]oestradiol complexes were then
successively extracted with 0.5 mol/l KCl or absolute
ethanol. Specific binding was calculated from the differ-
ence between radioactivity levels measured in the
absence and presence of unlabelled oestradiol and the
data were analyzed according to the method of Scatchard
[30]. EI was defined as a ratio of the specifically bound
[3H]oestradiol released with KCl to the total amount of the
specifically bound [3H]oestradiol extracted successively
with KCl and ethanol: EI = ([3H]oestradiol) [KCl] × 100/
([3H]oestradiol) [KCl] + ([3H]oestradiol) [EtOH]. High
values of EI were considered to indicate the absence of
ABC ER domains [11].
The same procedure was applied for [125I]TAZ, except
that a 5 nmol/l saturating concentration was used.
Because ethanol was unable to elute the covalently bound
[125I]TAZ from the ER in the final step of the conventional
hydroxylapatite assay, extraction of labelled receptor was
carried out with 0.5 mol/l phosphate. Bound [3H]oestra-
diol was measured with Ecoscint H scintillation fluid
(National Diagnostics, Atlanta, GA, USA) in a Wallac
1409 liquid scintillation counter (Wallac Oy, Turku,
Finland) with 45–60% counting efficiency; bound
[125I]TAZ was measured in a g-detector (Crystal 5400
Series, United Technologies Packard, IL, USA).
Heat treatment of breast tumour cytosols
Tumour cytosols were heated at 37°C for 2 min in the
presence or absence of a cocktail of protease inhibitors
(final concentrations: 1 mmol/l for AEBSF, antipain and
chymostatin; 5 mmol/l for PMSF; 0.1 mmol/l for leupeptin;
and 0.1 mg/ml for calpastatin). After treatment, samples
were labelled with 1 nmol/l [125I]TAZ (1 h at 0°C) in the
presence or absence of a 200-fold excess of radioinert
oestradiol, immunoprecipitated with H222 anti-ER mono-
clonal antibody, and then analyzed using SDS-PAGE.
SDS-PAGE analysis for cytosolic oestrogen receptors
ER preparations (cytosol/KCl extract from hydroxylapatite)
were covalently labelled with 1 nmol/l [125I]TAZ (1 h
incubation at 0°C) in the absence or presence of a 200-fold
excess of unlabelled oestradiol; unbound ligand was then
removed with DCC treatment. Labelled ERs were subse-
quently immunoprecipitated with H222, H226, or ER1D5
anti-ER monoclonal antibodies, and then antirat IgG
agarose was added. Resulting suspensions were cen-
trifuged and the pellets washed before being solubilized in
lysis buffer (4% SDS, 20% glycerol, 10% mercaptoethanol,
0.05% bromophenol blue in 500 mmol/l Tris-HCl; pH 6.8).
Lysates were subjected to electrophoresis on a 10% poly-
acrylamide gel in buffer (25 mmol/l Tris-HCl, 0.1% SDS,
192 mmol/l glycine; pH 8.2). Gels were stained, dried and
finally exposed to Kodak X-OMAT films (Eastman Kodak Cy,
Rochester, NY, USA) for 1 day for autoradiographical visual-
ization of radioactive bands [19]. The molecular weights of
the labelled peptides were estimated according to the
migration of 14–94 kDa protein standards (Amersham Phar-
macia Biotech, Uppsala, Sweden).
SDS-PAGE analysis for tissue oestrogen receptors
Sliced breast cancer tissues (thickness varied among
samples, but was always less than 0.5 mm) were incubated
for 1 h at 37°C with [125I]TAZ (final concentration 1 nmol/l)
in Krebs–Ringer phosphate buffer (pH 7.4), with 2% bovine
albumin and 0.25% glucose [31,32]. Then, all tissues were
washed with Krebs–Ringer phosphate buffer and mixed
with the same solution, but containing 1% SDS, 1.6 mmol/l
EDTA and 2% b-mercaptoethanol. Tissue slices were briefly
and delicately homogenized, and heated to 100°C for
2 min. Protein extraction was carried out by phenol and pre-
cipitation by acetone containing 0.1 mol/l acetic acid [32].
After 2 h at –20°C, the extracts were centrifuged. After
washing, the pellets were solubilized in lysis buffer and sub-
jected to electrophoresis as described above.
Oestrogen receptor mRNA measurement
Total RNA was extracted with TRIzol reagent
(Boehringer–Mannheim, Mannheim, Germany), dissolved
in RNase-free water and quantified by spectrophotometry
at 260–280 nm. Aliquots of 30 mg RNA/15 ml were elec-
trophoresed through a 1% agarose formaldehyde gel,
capillary transferred to a Hybond-N membrane (Amer-
sham), and treated according to the manufacturer’s
instructions. An EcoRI fragment (1300 pb) of pOR3 used
as an ER-a mRNA probe was from the American Type
Culture Collection (Rockville, MD, USA). Blots were
hybridized sequentially with [32P]-labelled ER cDNA probe
(109 cpm/mg cDNA, produced by random priming
[Boehringer Mannheim]). Prehybridization (4 h) and
hybridization (18 h) were performed as described previ-
ously [33]. The membranes were then washed with
sodium citrate solutions of increasing stringency, the last
wash being performed in 0.3 × sodium citrate solutions
containing 0.1% SDS. Blots were visualized by exposure
of the membranes for 1 day to Kodak XAR-5 film in an
autoradiography cassette with an intensifying screen.Immunohistochemistry
Breast cancer sections submitted to formalin fixation and
paraffin embedding were immunostained with ER1D5
monoclonal antibody (Immunotech, Marseille-Luminy,
France) using microwave pretreatment for antigen
retrieval. Briefly, the sections were soaked in buffer
(sodium citrate 10 mmol/l; pH 6) and heated for three
cycles, each for 5 min at 600 W. After microwave treat-
ment, sections were allowed to cool in room temperature
and incubated with ER1D5 (used at 1:150 dilution) for
1 h. Sections were processed using a multilink supersen-
sitive streptavidin-biotin detection system (Biogenex, San
Ramon, CA, USA), employing diaminobenzidine as chro-
mogen and haematoxylin counterstaining.
The nuclear staining was classified in intense, moderate,
weak or nonstained categories. The immunostaining score
(IS) was based on the staining intensity among these cate-
gories and on the percentage of stained cells. The IS was
defined as a weighted sum of the percentages in the fol-
lowing manner: IS = 4a + 2b + c, where a is the percent-
age of intensely stained cells, b is the percentage of
moderately stained cells and c is the percentage of weakly
stained cells [34]. This weighted distribution of positive
cells is based on the previously demonstrated linear rela-
tionship between the subjectively determined optical
density and the concentration of histochemical concentra-
tion product measured by microspectrophotometry [35].
Results
Adsorption of oestrogen isoforms onto hydroxylapatite at
low ionic strength
Previous studies from our laboratory [12,36] revealed that
ER preparations (human ER expressed in yeast, cytosols
from MCF-7 breast cancer cells and uterus) adsorbed
onto hydroxylapatite display a lower [3H]oestradiol-binding
capacity than those provided by the conventional DCC
assay; interference of the phosphocalcic matrix of the
hydroxylapatite with ligand binding was advocated to
explain this discrepancy. Assessment of cytosols from
human primary breast tumours revealed that this property
also holds for their receptors.
In 97 cases out of a series of 102 cytosols, assessment of
the binding parameters of [3H]oestradiol (multipoint
Scatchard plot analysis) gave Kd values of the same order
of magnitude for both assays (median Kd values of 0.30
for DCC and 0.40 nmol/l for hydroxylapatite; Table 1).
Binding capacities established by these two methods
were also significantly correlated (r = 0.79;  P < 0.001),
with systematically higher values for the DCC assay (slope
of the regression line = 1.47; Fig 1). The remaining five
outlayers bound [3H]oestradiol with a relatively lower affin-
ity (Kd about ten times higher; Table 1). These outliers
were also characterized by a weak [3H]oestradiol-binding
capacity by the DCC assay and a wide range of values by
the hydroxylapatite procedure (Fig. 1; inset). They did not
differ from the others with regard to their protein contents,
thus refuting the hypothesis of false-negative or false-posi-
tive cases associated with a low or high protein level [37].
The nature of these low affinity-binding sites remains
unknown.
Using [125I]TAZ instead of [3H]oestradiol as the labelling
agent in another series of 36 cytosols, we established a
similar correlation (r = 0.83; P < 0.001; Fig. 2). The slope
of the regression line was similar to that established with
[3H]oestradiol (1.40), indicating a similar interference of
the phosphocalcic matrix of the hydroxylapatite in the
binding of [125I]TAZ. Hence, at low ionic strength, ligand-
binding capacities of cytosolic ER from breast tumours are
significantly correlated when assessed by DCC and
hydroxylapatite assays.
Release of cleaved oestrogen receptor isoforms from
hydroxylapatite with KCl
Data reported above suggest that the ER domains that are
required for hydroxylapatite adsorption (ABC domains)
and ligand-binding (E domain) are present in most tumour
cytosols. In view of the high frequency of cleaved ER
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Figure 1
Comparison of [3H]oestradiol (E2)-binding capacities of a series of
human breast cancer cytosols simultaneously measured by DCC and
hydroxylapatite (HAP) assays (ethanolic extraction). The ordinate
corresponds to values established by DCC, and the abscissa to those
by hydroxylapatite (data established by Scatchard plot analysis). A
significant correlation was obtained between the two assays in 97 out
of 102 (95%) samples; five outlayers are represented by closed
symbols in the insert.isoforms in breast cancer [11], such domains should be
dissociated at high ionic strength, as demonstrated here
using [125I]TAZ as a labelling agent.
ER isoforms labelled with radiolabelled TAZ were easily
detected by successive immunoprecipitation and SDS-
PAGE (full-length 67 kDa and cleavage products of 50
and 37–28 kDa) [19,38,39]. Using this approach we
observed that a pool of breast cancer cytosols labelled
with [125I]TAZ gave different electrophoretic patterns,
depending on the nature of the anti-ER monoclonal anti-
body used in the immunoprecipitation step preceding
electrophoresis (H222, H226, ER1D5; Fig. 3a, left). The
carboxyl-terminal-specific antibody H222 precipitated all
ER isoforms, whereas the amino-terminal-specific antibod-
ies H226 and ER1D5 precipitated only the full-length and
http://breast-cancer-research.com/content/2/6/444
Table 1
Comparison of Kd values estimated by DCC and hydroxylapatite (HAP) assays in the whole series of human breast cancer cytosols
(102 cases) as well as in the five cases not included in the correlation
102 Cases 97 Cases 5 Cases
Range Median Range Median Range Median
Dissociation constants (nmol/l)
DCC 0.001–02.74 0.31 0.001–2.74 0.30 0.010–02.70 0.45
HAP 0.001–17.90 0.42 0.001–2.92 0.40 0.080–17.90 4.26
Protein (mg/ml)
0.80–11.00 4.52 0.80–11.00 4.41 0.80–10.11 4.01
Figure 2
Comparison of [125I]TAZ-binding capacities (5 nmol/l) of a series of
human breast cancer cytosols simultaneously measured by DCC and
hydroxylapatite (HAP) assays (phosphate extraction).
Figure 3
(A) Molecular weight and monoclonals anti-ER recognition of
[125I]TAZ-labelled ER isoforms extracted from hydroxylapatite (HAP)
with KCl. (left) Part of human breast cancer cytosol pool, after labelling
with 1 nmol/l [125I]TAZ for 1 h at 0°C in the presence or absence of a
200-fold excess of radioinert oestradiol, was immunoprecipitated with
H222, H226 or ER1D5 anti-ER monoclonal antibodies, and then
analyzed by SDS-PAGE and autoradiography. (right) Another part of
this cytosol pool was adsorbed onto HAP, labelled with 1 nmol/l
[125I]TAZ, extracted with 0.5 mol/l KCl, and immunoprecipitated before
being subjected to electrophoresis. (B) Presumed structure of ER
isoforms extracted from HAP with KCl. Potential sites of covalent
attachment of TAZ [40,41] are indicated by open circles; antigenic
sites for anti-ER monoclonal antibodies are shown above ER structure.
The predicted ER isoforms extracted from HAP as well as their sizes
determined by SDS-PAGE are shown below.
A Breast tumor cytosols KCl extract from HAP
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B
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a partially truncated 50 kDa isoform, indicating a lack of
corresponding antigenic sites in the 37–28 kDa isoforms.
Of note, the 50 kDa band was more intensely labelled with
H226. The [125I]TAZ-labelling intensity of all of these
bands was suppressed with a 200-fold excess of un-
labelled oestradiol, establishing their specificity.
Part of this [125I]TAZ-labelled cytosol pool was adsorbed
onto hydroxylapatite and subsequently subjected to KCl
extraction (Fig. 3a; right). Elutes were then immunoprecipi-
tated before being subjected to SDS-PAGE. Absence of
67 and 50 kDa isoforms under all immunoprecipitation
conditions confirmed their adherence onto hydroxylapatite
due to their strong interaction (ABC domains) with the
matrix. On the contrary, and as expected, ER isoforms with
a molecular weight of between 37 and 28 kDa were
detected in the elutes when the immunoprecipitation was
carried out by H222; their absence after exposure to
H226 or ER1D5 confirmed the cleavage of these isoforms
at a site(s) downstream of ABC domains. Hence, hydroxy-
lapatite extraction assay easily identifies ER isoforms that
lack amino-termini. Figure 3b illustrates the presumed
structure of these various ER isoforms, as well as their
sizes as determined by SDS-PAGE.
Assessment of oestrogen receptor mRNA size in breast
cancer
Total RNA from 46 breast tumours was qualitatively and
quantitatively analyzed by hybridization with an ER-a full-
length probe (Northern blotting). All tumours expressed a
full-length 6.6-kb ER mRNA (small-sized species were not
recorded). Moreover, a good correlation was obtained when
the amount of 6.6-kb ER mRNA estimated by densitometry
was compared with corresponding [3H]oestradiol-binding
capacities (DCC values; Fig. 4). Hence, ER isoforms of low
molecular weight did not appear to be encoded by trun-
cated ER mRNAs, suggesting that they were generated by
proteolysis. Whether such a phenomenon is an intracellular
process is analyzed below.
Origin of cleaved oestrogen receptor forms
Cytosol samples of a series of breast tumours were
labelled with [125I]TAZ in the presence of a cocktail of com-
pounds that are known to inhibit the action of a wide range
of proteolytic activities (final concentrations: 1 mmol/l for
AEBSF, antipain and chymostatin; 5 mmol/l for PMSF;
0.1 mmol/l for leupeptin; and 0.1 mg/ml for calpastatin);
this cocktail was added before or shortly after the homoge-
nization of the samples. These inhibitors failed to maintain
the native 67 kDa nature of the receptor as demonstrated
by SDS-PAGE and autoradiography (Fig. 5); the ER elec-
trophoretic pattern was not significantly modified, still
showing bands of low molecular weight.
In order to determine the molecular weight of intracellular
ER molecules, we applied an in situ labelling approach
Figure 4
Correlation between ER mRNA and ER (by DCC assay). Breast
tumours mRNA abundance (intensity of the 6.6-kb band) was
expressed relatively to mRNA levels in MCF-7 cells (MCF-7 = 1).
Figure 5
Effect of heat treatment on the relative expression of ER isoforms.
Human breast cancer cytosols were heated at 37°C for 2 min in the
presence or absence of protease inhibitors. They were then labelled
with [125I]TAZ in the presence or absence of a 200-fold excess of
radioinert oestradiol, immunoprecipitated with H-222 anti-ER
monoclonal antibodies, and then subjected to SDS-PAGE. Lane 1,
unheated control; lane 2, plus an excess of oestradiol; lane 3, 2 min
heating in the absence of protease inhibitors; lane 4, 2 min heating in
the presence of protease inhibitors.
MW
94
67
43
30
(kDa)
1234along with an extraction procedure to minimize ER proteo-
lysis [31,32]; tumour slices were incubated with [125I]TAZ
at 37°C before homogenization and lysis at 100°C in the
presence of SDS. Labelled proteins extracted with pheno-
lic solution were precipitated by acetone and finally identi-
fied by SDS-PAGE. ER electrophoretic patterns remained
almost identical to those usually found with cytosols, still
showing bands of truncated receptors (mainly 50 and
37–28 kDa; Fig. 6). Hence, the high proportion of the low-
molecular-weight isoforms appeared already to be present
within tumour samples.
Finally, breast cancer cytosols were heated at 37°C for
2 min in the absence or presence of a cocktail of protease
inhibitors in order to determine whether they possess pro-
teolytic activities that are able to cleave native ER.
Samples were subsequently adsorbed onto hydroxylap-
atite and successively subjected to KCl and ethanol
extraction. No significant increase in EI was recorded
(Table 2); inhibitors also failed to induce any drastic
change in EI values, refuting the hypothesis that isoforms
devoid of ABC domains may emerge during assay proce-
dures. Of note, treatment at 37°C of control preparations
of native ER (human recombinant ER, MCF-7 cells)
resulted in similar behaviour. Hence, major proteolysis did
not occur at the time of manipulation. Taken together,
these data suggest that dominant ER proteolytic cleavage
is an intracellular process.
Hydroxylapatite extraction index and heterogeneity of
oestrogen receptors
Data reported here clearly show that low-molecular-weight
ER isoforms extracted from hydroxylapatite matrix with KCl
were not recognized by the ER1D5 monoclonal antibody.
Because this antibody is often used in immunohistochemi-
cal assessment of ERs, we assessed whether immunohis-
tochemical data are related to hydroxylapatite ER
adsorption characteristics measured in cytosolic prepara-
tions from the corresponding tumours. For this purpose,
cytosols from a set of 15 ER-positive tumours (by DCC
assay), for which nuclear ERs had been detected by
immunohistochemistry (IS cutoff ³5), were labelled with
[3H]oestradiol and were then subjected to hydroxylapatite
assay (Table 3). A significant correlation between the two
sets of measurement was recorded (IS versus total
number of binding sites assayed by hydroxylapatite,
r = 0.71;  P < 0.001; Table 3). Sequential extraction of
bound [3H]oestradiol from hydroxylapatite with KCl and
ethanol revealed an EI of over 30% in the large majority of
these cytosols (11/15), indicating a high frequency of
cleaved ER. Of note, no significant correlation between IS
and EI data (r = 0.2;  P > 0.05) was detected, clearly
establishing that identification of ABC domains within the
cell (indicated by IS) does not imply the presence of
(native) full-length ER in the corresponding cytosol.
Discussion
Cytosolic ER contains several sites that are sensitive to
proteolytic cleavage. On limited digestion, ER fragments
of 50 and 37 kDa and lower molecular weight were
recorded in uterine cytosol preparations [42]. The pres-
ence of such isoforms has generally been attributed to
proteolysis of the native ER [43,44]. Regarding ER pre-
pared from breast cancer samples, we previously sug-
gested [11] that proteolytic events that operate at the time
of tissue processing might explain the observed extreme
ER molecular heterogeneity. Data presented here clearly
refute this hypothesis. A high proportion of these isoforms
is derived from an intracellular proteolytic activity, as
shown by electrophoresis of in situ [125I]TAZ-labelled ER
and addition of protease inhibitors to cytosols. In this
regard, the present results are in agreement with those
reported recently by Navarro et al [45] who demonstrated
that the inclusion of PMSF, aprotinin and leupeptin to
human uterine cytosolic ER did not prevent the 8S to 4S
transformation known to be associated with ER cleavage
[46]. Hence, truncated ER isoforms are probably pro-
duced before contact with protease inhibitors.
On breast tumour slices, staining intensities (ISs) estab-
lished with the ER1D5 monoclonal antibody used here have
often been reported to be correlated with [3H]oestradiol-
binding capacities of corresponding cytosolic extracts
[5,6,47]. Hence, a consensus seems to exist between
immunohistochemical detection of the amino-terminal
http://breast-cancer-research.com/content/2/6/444
Figure 6
In situ labelling of ER with [125I]TAZ. Breast tissues slices (samples
1–4, ER positive; sample 5, ER-negative) were incubated with 1 nmol/l
[125I]TAZ for 1 h at 0°C and the unbound ligand was removed. Then,
all tissues were mixed with Krebs–Ringer phosphate buffer containing
1% SDS, 1.6 mmol/l EDTA and 2% b-mercaptoethanol, and briefly
homogenized. After lysis at 100°C, proteins were extracted with
phenol, precipitated by acetone and were finally analyzed by SDS-
PAGE. The figure shows the electrophoretic patterns of these tissue
ERs.
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30region of ER (ABC domains) and biochemical measurement
of its carboxyl-terminal region (E domain). In agreement with
this, we reported a significant correlation between immuno-
histochemical data and [3H]oestradiol-binding capacities
measured by hydroxylapatite assay; ABC domains are
indeed required for hydroxylapatite adsorption [12]. For
both [3H]oestradiol- and [125I]TAZ labelled-ER isoforms, we
found an excellent correlation between DCC values and
hydroxylapatite adsorption data, suggesting the concomi-
tant presence of free ABC and E domains in most cytosols
(proteolytic fragments physically separated from each other
at high ionic strength; high EI values). Hence, these
domains would be held together within the cell nucleus
because of the tendency of the receptor to be included into
oligomeric structures. Corroborating these views of intracel-
lular association between ER fragments, Fritsch et al [42]
described large oligomeric complexes containing proteo-
lysis-generated ER fragments in rat uterus.
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Table 2
Comparison of EIs of adsorbed ER onto hydroxylapatite matrix in the absence and presence of protease inhibitors
EI (%)
Without protease inhibitors With protease inhibitors
ER 0°C 37°C 0°C 37°C
Cytosol from tumors 69 ± 9 82 ± 16 61 ± 7 59 ± 13
Recombinant hER <10 <10 <10 12 ± 5
MCF-7 cells <10 11 ± 2 13 ± 02 16 ± 4 
hER, human full-length ER.
Table 3
Comparative analysis of ER by immunohistochemistry (ER1D5), DCC ([3H]oestradiol-binding) and hydroxylapatite ([3H]oestradiol-
binding and EI)
Tissular ER Cytosolic ER
IHC DCC Hydroxylapatite
Case no. IS n (fmol/mg protein) n (fmol/mg protein)* EI (%)†
1 10 39 27 (20 + 7) 74.5
2 20 69 62 (54 + 8) 86.8
3 20 32 67 (21 + 46) 31.5
4 40 38 35 (12 + 23) 34.4
5 130 23 130 (91 + 39) 70.0
6 130 83 151 (62 + 89) 41.1
7 160 163 166 (30 + 136) 18.0
8 160–200 257 209 (58 + 151) 27.5
9 260 23 103 (64 + 39) 62.1
10 360 265 230 (114 + 116) 49.6
11 360–400 400 360 (190 + 170) 52.6
12 360–400 354 337 (82 + 255) 24.5
13 360–400 178 193 (60 + 133) 31.0
14 360–400 92 174 (36 + 138) 20.8
15 360–400 312 390 (156 + 234) 40.0
*Hydoxylapatite corresponds specifically to [3H]oestradiol extracted successively from hydroxylapatite with KCl and ethanol (ie 27 = 20 + 7). †EI =
([3H]oestradiol) [KCl] × 100/([3H]oestradiol) [KCl] + ([3H]oestradiol) [EtOH]. IHC, immunohistochemistry; IS, immunostaining score.When expressed individually as separate polypeptides in
ER-negative breast cancer cells (MDA-MB-231), neither
ABCD (AF-1 containing) nor EF (AF-2 containing)
domains activated transcription from a hormone-inducible
reporter gene (3ERE-pS2-CAT) [48]. Coexpression of the
steroid receptor coactivator-1 protein with either ABCD or
EF alone was also ineffective [49]. On the contrary, when
expressed together, amino- and carboxyl-terminal ER
regions interacted in an oestradiol-dependent manner to
reconstitute ER transcriptional activity [48]. In this context,
it should be emphasized that steroid receptor coactivator-
1 has also been suggested to promote the association
between separate amino- and carboxyl-terminal regions of
ER, allowing full ER activation [49]. In view of these data,
one may speculate that the secondary and tertiary struc-
tures of the receptor peptide required for its transcrip-
tional ability would not be lost when it has been subjected
to endogenous proteolytic activity. Hence, intracellular ER
fragmentation should not necessarily imply lack of tran-
scriptional activity.
Endogenous proteolysis is a mechanism of regulation of
many cellular processes, such as cell cycle progression
and transcriptional regulation [50,51]. Recent data con-
cerning cell-specific regulation of oestrogen target gene
expression in various rat tissues [52] and cell lines [53]
demonstrated different levels of coactivators and core-
pressors. Hence, protein environment would be a factor of
major importance in the ability of ER to transcribe genes.
Although not presently demonstrated in breast cancer, the
possibility of heterogeneous association between cleav-
age products of ER and other regulatory proteins could be
proposed, generating a situation that may mimic the
behaviour of chimaeric receptors. Thus, domain-swapping
experiments in which the ER amino-terminal domain was
switched with that of the glucocorticoid receptor yielded a
receptor that upregulates transcription of glucocorticoid-
responsive target genes when treated with oestradiol [54].
Investigation of homogenous association and/or heteroge-
neous association between cleaved ER regions and regu-
latory proteins would be informative with regard to the
validity of this hypothesis.
In view of these considerations, it seems that analysis of
the biological role and potential clinical relevance of
endogenous ER proteolysis is of prime importance. The
hydroxylapatite extraction assay described here, which is
extremely simple, would provide a criteria for the detection
of tumours characterized by a high amount of full-length
ER (low EI). Such tumours may perhaps be considered an
indication for adjuvant hormone therapy if we refer to
earlier sucrose gradient sedimentation data concerning
hormone dependency of tumours that express native
and/or cleaved ER forms [17]; very high EI may perhaps
be an index of poor prognosis. In practice, for clinical cor-
relation studies devoted to analysis of these hypotheses,
we propose that a hydroxylapatite extraction assay should
be performed as a complement to the usual immunohisto-
chemical test (or Abbott’s ER enzyme immunoassay [4]),
in view of the small size of most tumours that restrict the
cytosol amount. If our speculations concerning the biologi-
cal/clinical relevance of the detection of cleaved ER iso-
forms are verified, then the introduction of such a
hydroxylapatite assay into routine practice would be
helpful to orientate therapy.
Acknowledgement
This work was supported by grants from the Fonds Medic and the Fonds J-
C Heuson. YM is a recipient of a grant from the Fonds National de la
Recherche Scientifique – Télévie. ML is a recipient of a grant from Les Amis
de l’Institut Bordet. FJ is a recipient of a grant from the Fonds J-C Heuson.
We thank Dr A Buggenhout for reading of the manuscript.
References
1. Heuson JC, Leclercq G, Longeval E, Deboel MC, Mattheiem WH,
Heimann R: Estrogen receptors: pronostic significance in breast
cancer. In: Estrogen Receptors in Human Breast Cancer. Edited by
McGuire WL, Carbone PP, Volmer EP. New York: Raven Press,
1975:57–72.
2. McGuire WL: Hormone receptors: their role in predicting progno-
sis and response to endocrine therapy. Semin Oncol 1978, 5:
428–433.
3. DeSombre ER, King WJ, Green GL, Jensen EV: Estrogen receptor
studies. Laboratory investigations and clinical applications. In:
Estrogen/Antiestrogen Action and Breast Cancer Therapy. Edited by
Jordan VC. Wisconsin: University of Wisconsin Press, 1986:303–323.
4. Leclercq G, Bojar H, Goussard J, Nicholson RI, Pichon MF, Piffanelli
A, Pousette A, Thorpe S, Lonsdorfer M: Abbott monoclonal enzyme
immunoassay measurement of estrogen receptors in human
breast cancer: a european multicenter study. Cancer Res 1986, 46
(Suppl):S4233–S4236.
5. al Saati T, Clamens S, Cohen-Knafo E, Faye JC, Prats H, Coindre JM,
Wafflart J, Caveriviere P, Bayard F, Delsol G: Production of mono-
clonal antibodies to human estrogen-receptor protein (ER) using
recombinant ER (RER). Int J Cancer 1993, 55:651–654.
6. Kell DI, Kamel OW, Rouse RV: Immunohistochemical analysis of
breast carcinoma estrogen and progesterone receptors in paraf-
fin-embedded tissues: correlation of clones ER1D5 and 1A6 with
a cytosol-based hormone receptor assay. Appl Immunohistochem
1993, 1:275–281.
7. Wong SY, Purdie A, Sewell HF, Wilkinson L, Angus B, Westley B,
Horne CH: Immunohistochemical assessment of ER-P31, a mouse
anti-oestrogen receptor protein monoclonal antibody in human
breast cancers: comparison with ER-ICA (Abbott) and radioligand
assays. Tumor Biol 1991, 12:16–23.
8. Clark GM, McGuire WL: Steroid receptors and other pronostic
factors in primary breast cancer. Semin Oncol 1988, 15:20–25.
9. Wittliff JL: Steroid-hormone receptors in breast cancer. Cancer
1984,  53:630–643.
10. Sluyser M, Wittliff JL: Influence of estrogen receptor variants in
mammary carcinomas on the pronostic reliability of the receptor
assay. Mol Cell Endocrinol 1992, 85:83–88.
11. Maaroufi Y, Trivedi S, Leclercq G: Major molecular weight hetero-
geneity of estrogen receptor from breast cancer is not related to
neoplasia. Cancer Biochem Biophys 1995, 15:67–78.
12. Maaroufi Y, Leclercq G: Importance of A/B and C domains of the
estrogen receptor for its adsorption to hydroxylapatite. J Ster
Bioch Mol Biol 1994, 48:155–163.
13. Murayama A, Fukai F, Murachi T: Action of calpain on the basic
estrogen receptor molecule of porcine uterus. J Biochem 1984,
95:1697–1704.
14. Thole HH, Maschler I, Jungblut PW: Surface mapping of the ligand-
filled C-terminal half of the porcine estradiol receptor by restricted
proteolysis. Eur J Biochem 1995, 231:510–516.
15. Seielstad DA, Carlson KE, Kushner PJ, Greene GL, Katzenellenbogen
JA: Analysis of the structural core of the human estrogen receptor
ligand binding domain by selective proteolysis/mass spectrome-
try analysis. Biochemistry 1995, 34:12605–12615.
http://breast-cancer-research.com/content/2/6/444Breast Cancer Research    Vol 2 No 6 Maaroufi et al
16. Horigome TF, Ogata TS, Golding F, Korach KS: Estradiol-stimulated
proteolytic cleavage of the estrogen receptor in mouse uterus.
Endocrinology 1988,  123:2540–2548.
17. Wittliff JL, Savlov ED: Estrogen binding capacity of cytoplasmic
forms of estrogen receptors in human breast cancer. In: Estrogen
Receptors in Human Breast Cancer. Edited by McGuire WL, Carbone
PP, Volmer EP. New York: Raven Press, 1975:73–86.
18. Freedman B, Hawkins RA: Sedimentation profiles of the estrogen
receptor from breast tumors of man and rat using vertical-tube
rotor centrifugation. J Endocrinol 1980, 86:431–442.
19. Piccart MJ, Muquardt C, Bosman C, Pirotte P, Veenstra S, Grillo F,
Leclercq G: Comparison between tritiated estradiol and tamoxifen
aziridine for measuring estrogen receptors in human breast
cancer cytosols. J Natl Cancer Inst 1991, 83:1553–1559.
20. Pahl HL, Bäuerle PA: Control of gene expression by proteolysis.
Curr Opin Cell Biol 1996, 8:340–347.
21. Spataro V, Norbury C, Harris AL: The ubiquitin-proteasome
pathway in cancer. Br J Cancer 1998, 77:448–455.
22. Plombella VJ, Rando OJ, Goldberg AL, Maniatis T: The ubiquitin-pro-
teasome pathway is required for processing the NF-kappa B1
precursor protein and the activation of NF-kappa B. Cell 1994, 78:
773–785.
23. Bäuerle PA, Baltimore D: NF-k kB: ten years after. Cell 1996, 87:
13–20.
24. El Khissiin A, Leclercq G: Implication of proteasome in estrogen
receptor degradation. FEBS Lett 1999, 448:160–166.
25. Nawaz Z, Lonard DM, Dennis AP, Smith CL, O’Malley BW: Protea-
some-dependent degradation of the human estrogen receptor.
Proc Natl Acad Sci USA 1999, 96:1858–1862.
26. Alarid ET, Bakopoulos N, Solodin N: Proteasome-mediated proteol-
ysis of estrogen receptor: a novel component in autologous
down-regulation. Mol Endocrinol 1999, 13:1522–1534.
27. Wooge CH, Nilsson GM, Heierson A, McDonnell DP, Katzenellenbo-
gen BS: Structural requirements for high affinity ligand binding by
estrogen receptors: a comparative analysis of truncated and full
length estrogen receptors expressed in bacteria, yeast, and mam-
malian cells. Mol Endocrinol 1992, 6:861–869.
28. Leclercq G, Legros N, Piccart MJ: Accumulation of a non-binding
form of estrogen receptor in MCF-7 cells under hydroxytamoxifen
treatment. J Steroid Biochem Mol Biol 1992, 41:545–552.
29. EORTC: Breast Cancer Cooperative Group. Revision of the stan-
dards for the assessment of hormone receptors in human breast
cancer. Eur J Cancer 1980, 16:1513–1515.
30. Scatchard G: The attraction of proteins for small molecules and
ions. Ann NY Acad Sci 1949, 51:660–672.
31. Terenius L: Selective retention of estrogen isomers in estrogen-
dependent breast tumors of rats demonstrated by in vitro
methods. Cancer Res 1968, 28:328–337.
32. Toulas C, Guilbaud N, Delassus F, Bayard F, Faye JC: Modulation of
the estrogen receptor structure, evidence of a heterogeneity. J
Receptor Res 1990, 10:1–9.
33. Borràs M, Lacroix M, Legros N, Leclercq G: Estrogen receptor-nega-
tive/progesterone receptor-positive Evsa-T mammary tumor cells:
a model for assessing the biological property of this peculiar phe-
notype of breast cancers. Cancer Lett 1997, 120:23–30.
34. Deugnier Y, Margules S, Brissot P, Deugnier MA, Bisconte JC, Bourel
M, Ferrand B: Comparative study between biochemical and histo-
logical methods and image analysis in liver iron overload. J Clin
Pathol 1982, 35:45–51.
35. Weintraub J, Weintraub D, Redard M, Vassilakos P: Evaluation of
estrogen receptors by immunocytochemistry on fine-needle aspi-
ration biopsy specimens from breast tumors. Cancer 1987, 60:
1163–1172.
36. Maaroufi Y, Ben Hardouze A, Leclercq G: Decrease of estrogen
receptor binding capacity by calcium. J Receptor Signal Transduc-
tion Res 1997, 17:833–853.
37. Powel BL, de la Graza M, Clark GM, McGuire WL: Estrogen receptor
measurement in low protein breast cancer cytosols. Breast Cancer
Res Treat 1981, 1:33–35.
38. Trivedi S, Piccart M, Muquardt C, Gilot N, Hadiy S, Patel D, Leclercq
G: Tamoxifen aziridine labeling of the estrogen receptor: potential
utility in detecting biologically aggressive breast tumors. Breast
Cancer Res Treat 1996, 40:231–241.
39. Maaroufi Y, Quivy J, Trivedi S, Gilot N, Leclercq G: 4-iodotamoxifen
aziridine, a new affinity labeling agent for the rapid detection of
estrogen receptor isoforms. J Steroid Biochem Mol Biol 1998, 67:
95–104.
40. Harlow KW, Smith DN, Katzenellenbogen JA, Greene GL, Katzenellen-
bogen BS: Identification of cysteine 530 as the covalent attach-
ment site of an affinity-labeling estrogen (ketonenestrol aziridine)
and antiestrogen (tamoxifen aziridine) in the human estrogen
receptor. J Biol Chem 1989, 264:17476–17485.
41. Reese JC, Wooge CH, Katzenellenbogen BS: Identification of two
cysteines closely positioned in the ligand binding pocket of the
human estrogen receptor: roles in ligand binding and transcrip-
tional activity. Mol Endocrinol 1992, 6:2160–2166.
42. Fritsch M, Anderson I, Gorski J: Structural characterization of
trypsinized estrogen receptor. Biochemistry 1993, 32:14000–14008.
43. Wilson EA, Yang F, Rees D: Estradiol and progesterone binding in
uterine leiomyomata and in normal uterine tissues. Obstet
Gynecol 1980,  55:20–24.
44. Gregory MR, Notides AC: Characterization of two uterine pro-
teases and their actions on the estrogen receptor. Biochemistry
1982, 21:6452–6458.
45. Navarro D, León L, Chirino R, Fernández L, Pestano J, Díaz-Chico BN:
The two native estrogen receptor forms of 8S and 4S present in
cytosol from human uterine tissues display opposite reactivities
with the antiestrogen tamoxifen aziridine and the estrogen
responsive element. J Steroid Biochem Mol Biol 1998, 64:49–58.
46. Schneider SL, Dao TL: Effect of Ca2+ and salt on forms of estradiol
cytoplasmic receptor in human neoplasmic breast tissue. Cancer
Res 1977, 37:382–387.
47. Mauri FA, Veronese S, Frigo B, Girlando S, Losi L, Gambacorta M,
Dalla Palma P, Barbareschi M: ER1D5 and H222 (ER-ICA) antibod-
ies to human estrogen receptor protein in breast carcinomas:
results of a multicentric comparative study. Appl Immunohistochem
1994, 2:157–163.
48. Kraus WL, McInerney EM, Katzenellenbogen BS: Ligand-dependent,
transcriptionally productive association of the amino- and car-
boxyl-terminal regions of a steroid hormone nuclear receptor.
Proc Natl Acad Sci USA 1995, 92:12314–12318.
49. McInerney EM, Tsai MJ, O’Malley BW, Katzenellenbogen BS: Analy-
sis of estrogen receptor transcriptional enhancement by a nuclear
hormone receptor coactivator. Proc Natl Acad Sci USA 1996, 93:
10069–10073.
50. Hochstrasser M: Ubiquitin, proteasomes, and the regulation of
intracellular protein degradation. Curr Opin Cell Biol 1995, 7:215–
223.
51. King RW: How proteolysis drives the cell cycle. Science 1996, 274:
1652–1659.
52. Misiti S, Schomburg L, Yen PM, Chin WW: Expression and hor-
monal regulation of coactivator and corepressor genes.
Endocrinology  1998,  139:2493–2500.
53. Folkers GE, van der Burg B, van der Saag PT: Promoter architecture,
cofactors, and orphan receptors contribute to cell-specific activa-
tion of the retinoid acid receptor beta2 promoter. J Biol Chem
1998,  273:32200–32212.
54. Green S, Chambon P: Oestradiol induction of a glucocorticoid-
responsive gene by a chimaeric receptor. Nature 1987, 325:75–78.
Authors’ affiliations: Younes Maaroufi, Marc Lacroix, Fabrice Journé,
Guy Leclercq (Laboratoire J-C Heuson de Cancérologie Mammaire,
Service de Médecine, Institut Jules Bordet, Brussels, Belgium), and
Laurence Lespagnard and Denis Larsimont (Département d’Anatomie
Pathologique, Institut Jules Bordet, Brussels, Belgium)
Correspondence: Guy Leclercq PhD, Laboratoire J-C Heuson de
Cancérologie Mammaire, Service de Médecine. Institut Jules Bordet, 
1 Rue Héger-Bordet, 1000 Brussels, Belgium. Tel: +322 541 3744;
fax: +322 541 3498; e-mail: lcanmamm@ulb.ac.be